December 1, 2016

David S. Hilzenrath

At an August 15, 2016, public forum convened by the Food and Drug Administration, panelist Marc Boutin introduced himself as CEO of National Health Council and said his organization provides “a united voice for people with chronic disease and disabilities.”

Speaking at the agency’s invitation, he proceeded to praise a far-reaching deal the FDA had struck with the pharmaceutical lobby—a bargain designed in part to speed FDA approval of new drugs.